<DOC>
	<DOCNO>NCT02512900</DOCNO>
	<brief_summary>To evaluate PK profile single-dose 140 mg subcutaneous ( SC ) administration MEDI9929 ( AMG 157 ) adolescent subject mild moderate asthma .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics MEDI9929 ( AMG 157 ) Adolescents With Mild Moderate Asthma</brief_title>
	<detailed_description>The primary objective evaluate PK profile single-dose 140 mg subcutaneous ( SC ) administration MEDI9929 ( AMG 157 ) adolescent subject mild moderate asthma . The secondary objective evaluate safety tolerability MEDI9929 evaluate immunogenicity MEDI9929 ( AMG 157 ) . The exploratory objective evaluate effect MEDI9929 ( AMG 157 ) pulmonary function</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion Criteria Age 12 17 year ( inclusive ) screen Day 1 . Physician diagnose asthma minimum 6 month prior screen . Physician prescribed daily use asthma controller medication Prebronchodilator FEV1 ≥ 70 % predict normal value screening . A postbronchodilator increase FEV1 ≥ 12 % ≥ 200 mL screening . If allergen immunotherapy , subject must stable maintenance dose schedule ≥ 1 month prior Visit 1 . Weight ≥ 30 kg screen Day 1 . Body mass index age screen Day 1 5th 95th percentile Females childbearing potential sexually active nonsterilized male partner must use highly effective contraception screen Nonsterilized male sexually active female partner childbearing potential must use highly effective method contraception screen History deterioration asthma require burst systemic corticosteroid within 3 month screen , include Day 1 . Clinical characteristic either screen Day 1 consistent uncontrolled asthma describe GINA guideline . History hospitalization ( overnight admission ) asthma 6 month prior screen . History intubation management deterioration asthma . History systemic corticosteroid use maintenance treatment asthma within 3 month prior screen . History allergy reaction component investigational product formulation history anaphylaxis follow biologic therapy . Any active medical condition asthma , opinion investigator and/or medical monitor , may compromise safety subject study interfere evaluation investigational product reduce subject 's ability participate study ( subject atopic skin condition allergic rhinitis permit ) . Pregnant breastfeeding female . Current tobacco smoking cessation smoking ≤ 6months prior screening . Any clinically relevant abnormal finding opinion investigator medical monitor , may compromise safety subject study interfere evaluation investigational product reduce subject 's ability participate study . Evidence active liver disease , Positive hepatitis B hepatitis C virus A positive human immunodeficiency virus ( HIV ) test screen subject take antiretroviral medication Major surgery within 8 week prior Visit 1 , plan inpatient surgery hospitalization study period . History known primary immunodeficiency disorder History clinically significant infection A helminth parasitic infection within 24 week Visit 1 treat responded standard care therapy . History cancer .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Asthma</keyword>
</DOC>